Market Research Logo

United States Insulin Delivery Market Outlook to 2022

United States Insulin Delivery Market Outlook to 2022

Summary

GlobalData’s new report, United States Insulin Delivery Market Outlook to 2022, provides key market data on the United States Insulin Delivery market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segments - Insulin Pens, Insulin Pumps, Insulin Syringes and Traditional Insulin Pump Accessories.

The report also provides company shares and distribution shares data for each of these market segements, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

  • Market size and company share data for Insulin Delivery market segments - Insulin Pens, Insulin Pumps, Insulin Syringes and Traditional Insulin Pump Accessories.
  • Annualized market revenues (USD million) and volume (units) data for each of the market segements. Data is provided from 2008 to 2015 and forecast to 2022.
  • 2015 company shares and distribution shares data for each of the market segements.
  • Global corporate-level profiles of key companies operating within the United States Insulin Delivery market.
  • Key players covered include Medtronic plc, Becton Dickinson and Co, Eli Lilly and Company, Novo Nordisk A/S and Others.
Reasons to buy
  • Develop business strategies by identifying the key market segments poised for strong growth in the future.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
2.2 Insulin Delivery Market Segmentation
2.3 Definitions of Markets Covered in the Report
3 Insulin Delivery Market, United States
3.1 Insulin Delivery Market, United States, Revenue ($m), 2008-2015
3.2 Insulin Delivery Market, United States, Revenue ($m), 2015-2022
3.2.1 Insulin Pens Market, United States, Revenue ($m), by Segment, 2008-2015
3.2.2 Insulin Pumps Market, United States, Revenue ($m), by Segment, 2008-2015
3.2.3 Insulin Pens Market, United States, Revenue ($m), by Segment, 2015-2022
3.2.4 Insulin Pumps Market, United States, Revenue ($m), by Segment, 2015-2022
3.3 Insulin Delivery Market, United States, Volume (Units), 2008-2015
3.4 Insulin Delivery Market, United States, Volume (Units), 2015-2022
3.4.1 Insulin Pens Market, United States, Volume (Units), by Segment, 2008-2015
3.4.2 Insulin Pumps Market, United States, Volume (Units), by Segment, 2008-2015
3.4.3 Insulin Pens Market, United States, Volume (Units), by Segment, 2015-2022
3.4.4 Insulin Pumps Market, United States, Volume (Units), by Segment, 2015-2022
3.5 Insulin Delivery Market, United States, Average Price ($), 2008-2022
3.6 Insulin Delivery Market, United States, Distribution Share by Revenue ($m), 2014-2015
3.7 Insulin Delivery Market, United States, Company Share by Revenue ($m), 2015
4 Overview of Key Companies in United States, Insulin Delivery Market
4.1 Medtronic plc
4.1.1 Company Overview
4.2 Eli Lilly and Company
4.2.1 Company Overview
4.3 Becton Dickinson and Co
4.3.1 Company Overview
4.4 Novo Nordisk A/S
4.4.1 Company Overview
4.5 Insulet Corp
4.5.1 Company Overview
4.6 Sanofi
4.6.1 Company Overview
4.7 Tandem Diabetes Care, Inc.
4.7.1 Company Overview
4.8 F. Hoffmann-La Roche Ltd
4.8.1 Company Overview
4.9 B. Braun Melsungen AG
4.9.1 Company Overview
5 Insulin Delivery Market Pipeline Products
6 Financial Deals Landscape
6.1 Acquisition
6.1.1 MannKind May Sell Itself
6.2 Debt Offerings
6.2.1 Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million
6.2.2 Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million
6.2.3 Insulet Raises Private Placement of Senior Notes for USD300 Million
6.3 Equity Offerings
6.3.1 ConvaTec Raises USD1.8 Billion in IPO
6.3.2 Mannkind Prices Shares Issue for USD50 Million
6.3.3 Valeritas Raises USD25 Million in Private Placement of Shares
6.4 Partnerships
6.4.1 Becton, Dickinson Enters into Research Agreement with Juvenile Diabetes Research Foundation
6.4.2 Metabolon Enters into Licensing Agreement with Synlab
6.5 Venture Financing
6.5.1 Dance Biopharm Raises USD0.625 Million in Venture Financing
7 Recent Developments
7.1 Corporate Communications
7.1.1 Nov 30, 2016: Valeritas Elects Joe Mandato, Ph.D., Experienced Medical Device Executive and Investor, to Board of Directors
7.1.2 Oct 31, 2016: Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer
7.1.3 Oct 05, 2016: Henry Ford Health System Announces New CEO of Health Alliance Plan
7.1.4 Sep 22, 2016: Industry Veteran Katherine D. Crothall, PhD to Join Valeritas Board of Directors
7.1.5 Sep 14, 2016: Levi Garraway, M.D., Ph.D., to become Senior Vice President of Global Oncology at Lilly, Succeeding Richard Gaynor, M.D., Who is Retiring after a Distinguished Career
7.1.6 Sep 06, 2016: Insulet Announces Executive Appointments
7.1.7 Aug 31, 2016: Jamere Jackson Elected To Lilly Board Of Directors
7.1.8 Aug 16, 2016: Valeritas Appoints Erick J. Lucera as Chief Financial Officer
7.1.9 Aug 10, 2016: Lilly announces Joshua Smiley, Anat Ashkenazi appointed to new roles, Thomas Grein retires
7.1.10 Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors
7.1.11 Jul 27, 2016: John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor
7.1.12 Jul 13, 2016: Valeritas Appoints Brian K. Roberts to its Board of Directors
7.1.13 Jun 27, 2016: ConvaTec Provides Business Updates
7.1.14 Jun 23, 2016: Valeritas Appoints David Lewis as Vice President of Marketing
7.1.15 Jun 22, 2016: Johnson & Johnson Announces Retirement of Louise Mehrotra and Appointment of Joseph Wolk as Vice President of Investor Relations
7.1.16 Jun 13, 2016: Aarti Shah named chief information officer
7.1.17 Jun 02, 2016: Nektar Therapeutics Announces Executive Management Promotions
7.1.18 Apr 25, 2016: Peter J. Devlin Joins Valeritas Board of Directors as Independent Director
7.1.19 Apr 19, 2016: Rodney D. Altman, MD Joins Valeritas Board of Directors
7.1.20 Apr 08, 2016: Dr. Henry Anhalt to Step Down From Tandem Diabetes Care Board of Directors to Ensure No Risk of Potential Conflict of Interest
7.1.21 Mar 16, 2016: Insulet Names Aiman Abdel-Malek, Ph.D. Senior Vice President of Advanced Technology and Engineering
7.1.22 Mar 14, 2016: Tandem Diabetes Care Announces Appointment of Dr. Henry Anhalt as Board Member
7.1.23 Mar 14, 2016: MannKind Announces Appointment of Michael Castagna as Chief Commercial Officer
7.1.24 Mar 02, 2016: Insulet Announces Organizational Enhancements
7.1.25 Feb 25, 2016: Valeritas Announces Leadership and Board of Directors Changes
7.1.26 Feb 09, 2016: Insulet Appoints David A. Lemoine to Board of Directors
7.1.27 Feb 02, 2016: Tandem Diabetes Care Expands Commercial Leadership
7.1.28 Jan 26, 2016: Antares Pharma Announces CEO Transition
7.1.29 Jan 19, 2016: Johnson & Johnson Announces Actions To Strengthen Medical Devices Leadership Position In Evolving Healthcare Marketplace
7.1.30 Dec 23, 2015: MannKind Announces Appointment of Duane DeSisto as Chief Executive Officer
7.2 Financial Announcements
7.2.1 Nov 14, 2016: Retractable Technologies Reports Results as of September 30, 2016
7.2.2 Nov 10, 2016: Valeritas Reports Third Quarter 2016 Financial Results
7.2.3 Nov 09, 2016: Antares Pharma Reports Third Quarter 2016 Financial and Operating Results
7.2.4 Nov 09, 2016: Aradigm Announces Third Quarter 2016 Financial Results
7.2.5 Nov 09, 2016: MannKind Reports 2016 Third Quarter Financial Results
7.2.6 Nov 03, 2016: Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016
7.2.7 Nov 03, 2016: BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance
7.2.8 Nov 03, 2016: Insulet Reports Third Quarter 2016 Financial Results
7.2.9 Nov 01, 2016: Tandem Diabetes Care Reports Third Quarter 2016 Financial Results
7.2.10 Oct 25, 2016: Lilly Reports Third-Quarter 2016 Results
7.2.11 Oct 18, 2016: Johnson & Johnson Reports 2016 Third-Quarter Results
7.2.12 Aug 16, 2016: Retractable Technologies Reports Results as of June 30, 2016
7.2.13 Aug 10, 2016: Aradigm Announces Second Quarter 2016 Financial Results
7.2.14 Aug 10, 2016: Valeritas Reports Second Quarter 2016 Financial Results
7.2.15 Aug 09, 2016: Antares Pharma Reports Second Quarter 2016 Operating and Financial Results
7.2.16 Aug 08, 2016: MannKind Reports 2016 Second Quarter Financial Results
7.2.17 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter
7.2.18 Aug 03, 2016: Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016
7.2.19 Aug 03, 2016: Insulet Reports Second Quarter 2016 Financial Results
7.2.20 Jul 28, 2016: Integer Holdings Reports 2016 Second Quarter Results
7.2.21 Jul 26, 2016: Lilly Reports Second-Quarter 2016 Results, Provides Financial Expectations Through The Remainder Of The Decade
7.2.22 Jul 19, 2016: Johnson & Johnson Reports 2016 Second-Quarter Results
7.2.23 May 17, 2016: Retractable Technologies Reports Results for the First Quarter of 2016
7.2.24 May 10, 2016: Aradigm Announces First Quarter 2016 Financial Results
7.2.25 May 09, 2016: Antares Pharma Reports First Quarter 2016 Operating and Financial Results
7.2.26 May 09, 2016: MannKind Reports 2016 First Quarter Financial Results
7.2.27 May 03, 2016: Insulet Reaffirms Second Quarter and Full Year 2016 Guidance
7.2.28 Apr 28, 2016: Greatbatch Reports 2016 First Quarter Results
7.2.29 Apr 28, 2016: Tandem Diabetes Care Reports First Quarter 2016 Financial Results and Updates 2016 Guidance
7.2.30 Apr 28, 2016: Insulet Reports First Quarter 2016 Financial Results
7.2.31 Apr 19, 2016: Johnson & Johnson Reports 2016 First-Quarter Results
7.2.32 Apr 01, 2016: Retractable Technologies Reports Results for the Year 2015
7.2.33 Mar 08, 2016: Antares Pharma Reports Fourth Quarter and Full Year 2015 Operating and Financial Results
7.2.34 Feb 29, 2016: Greatbatch Reports 2015 Fourth Quarter and Full Year Results
7.2.35 Feb 25, 2016: Insulet Reports Fourth Quarter and Full Year 2015 Financial Results
7.2.36 Feb 24, 2016: Tandem Diabetes Care Reports Fourth Quarter and Full Year 2015 Financial Results
7.2.37 Jan 26, 2016: Johnson & Johnson Reports 2015 Fourth-Quarter Results
7.2.38 Jan 11, 2016: Greatbatch Provides Preliminary 2015 Revenue Results and 2016 Guidance
7.3 Legal And Regulatory
7.3.1 Dec 02, 2016: Retractable Technologies Reports on Fifth Circuit's Opinion
7.3.2 Nov 15, 2016: Henry Ford Radiation Oncology Receives 3-Year ACR Accreditation
7.3.3 Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic
7.3.4 Jun 10, 2016: Insulet Partners with Joslin Diabetes Center to Implement a Unique Training Certification for Insulet's Clinical Team
7.3.5 Apr 18, 2016: Henry Ford Breast Cancer Program Granted 3-Year Accreditation
7.3.6 Mar 14, 2016: DECN Subsidiaries Sue Johnson & Johnson and Several Divisions for Patent Infringement
7.3.7 Feb 29, 2016: Baron & Budd Investigating Potential Lawsuits Against Johnson & Johnson Regarding Link Between Talcum Powder and Ovarian Cancer
7.4 Other Significant Developments
7.4.1 Dec 15, 2016: Lilly Provides 2017 Financial Guidance And 2016 Update, Reaffirms Financial Expectations Through The Remainder Of The Decade
7.4.2 Oct 05, 2016: T1D Exchange Initiates Multi-million Dollar Investment in Automated Insulin Delivery Technologies
7.4.3 Sep 06, 2016: Insulet to Establish Highly-Automated Manufacturing Operation in the United States
7.4.4 Jul 28, 2016: Tandem Diabetes Care Reports Second Quarter 2016 Financial Results
7.4.5 Jun 27, 2016: Greatbatch Renamed Integer Holdings
7.5 Strategy And Business Planning
7.5.1 Nov 22, 2016: Highly Pathogenic Bird Flu Spreading Across Europe and Asia; BiondVax’s Universal Flu Vaccine Candidate Also Covers these Potential Pandemic Strains
7.5.2 Apr 11, 2016: CeQur Initiates Significant Facility Expansion in Marlborough
7.5.3 Apr 05, 2016: Allegiance Health Joins Henry Ford Health System
7.5.4 Jan 25, 2016: AstraZeneca partners with peers and academia to establish translational research fund
8 Appendix
8.1 Research Methodology
8.1.1 Coverage
8.1.2 Secondary Research
8.1.3 Primary Research
8.1.4 Company Share Analysis
8.1.5 Distribution Share Analysis
8.1.6 Benchmarking
8.2 GlobalData Consulting
8.3 Contact Us
8.4 Disclaimer
1.1 List of Tables
Table 1: Insulin Delivery Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015
Table 2: Insulin Delivery Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022
Table 3: Insulin Pens Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015
Table 4: Insulin Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015
Table 5: Insulin Pens Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022
Table 6: Insulin Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022
Table 7: Insulin Delivery Market, United States, Volume (Units), Historic, 2008-2015
Table 8: Insulin Delivery Market, United States, Volume (Units), Forecast, 2015-2022
Table 9: Insulin Pens Market, United States, Volume (Units), Historic, 2008-2015
Table 10: Insulin Pumps Market, United States, Volume (Units), Historic, 2008-2015
Table 11: Insulin Pens Market, United States, Volume (Units), Forecast, 2015-2022
Table 12: Insulin Pumps Market, United States, Volume (Units), Forecast, 2015-2022
Table 13: Insulin Delivery Market, United States, Average Price ($) Historic, 2008-2022
Table 14: Insulin Delivery Market, United States, Average Price ($), Forecast, 2015-2022
Table 15: Insulin Delivery Market, United States, Distribution Share by Revenue ($m), USD Constant, 2014-2015
Table 16: Insulin Delivery Market, United States, Company Share by Revenue ($m), USD Constant, 2015
Table 17: Insulin Delivery Market Pipeline Products
Table 18: MannKind May Sell Itself
Table 19: Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million
Table 20: Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million
Table 21: Insulet Raises Private Placement of Senior Notes for USD300 Million
Table 22: ConvaTec Raises USD1.8 Billion in IPO
Table 23: Mannkind Prices Shares Issue for USD50 Million
Table 24: Valeritas Raises USD25 Million in Private Placement of Shares
Table 25: Becton, Dickinson Enters into Research Agreement with Juvenile Diabetes Research Foundation
Table 26: Metabolon Enters into Licensing Agreement with Synlab
Table 27: Dance Biopharm Raises USD0.625 Million in Venture Financing
1.2 List of Figures
Figure 1: Insulin Delivery Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015
Figure 2: Insulin Delivery Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022
Figure 3: Insulin Pens Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015
Figure 4: Insulin Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015
Figure 5: Insulin Pens Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022
Figure 6: Insulin Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022
Figure 7: Insulin Delivery Market, United States, Volume (Units), Historic, 2008-2015
Figure 8: Insulin Delivery Market, United States, Volume (Units), Forecast, 2015-2022
Figure 9: Insulin Pens Market, United States, Volume (Units), Historic, 2008-2015
Figure 10: Insulin Pumps Market, United States, Volume (Units), Historic, 2008-2015
Figure 11: Insulin Pens Market, United States, Volume (Units), Forecast, 2015-2022
Figure 12: Insulin Pumps Market, United States, Volume (Units), Forecast, 2015-2022
Figure 13: Insulin Delivery Market, United States, Company Share (%) 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report